Preventive effect of high doze digestive enzyme management on development of fatty liver after pancreaticoduodenactomy: a randomized controlled study

Preventive effect of high doze digestive enzyme management on development of fatty liver after pancreaticoduodenactomy: a randomized controlled study - Preventive effect of high doze digestive enzyme management on development of fatty liver after pancreaticoduodenactomy: a randomized controlled study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005595

Enrollment

Registered

2012-06-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Planned to undergo pancreaticoduodenectomy

Interventions

Control group: Oral administration of digestive enzymes (common doze) for at least 12 months after pancreaticoduodenectomy Test group: Oral administration of digestive enzymes (high doze) for at leas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Planned to undergo pancreaticoduodenectomy R0 operation ASA score 1-3 Adequate organ function Written informed consent

Exclusion criteria

Exclusion criteria: Active infection Emergency operation Fatty liver (pre-operation) Uncontrolled diabetes mellitus Alcohol intake (post-operation) Positive HBs antigen or HCV antibody ASA score 4 and more Other reason that attending doctors consider

Design outcomes

Primary

Measure	Time frame
Rate of fatty liver development	—

Secondary

Measure	Time frame
Analysis of contributing factor in development of fatty liver	—

Countries

Japan

Contacts

Public ContactTakahide Yokoyama

Shinshu University School of Medicine Department of Surgery

tyoko@shinshu-u.ac.jp0263-37-2654

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026